

JC07 Rec'd PCT/PTO TT MAY 2001

PATENT APPLICATION

1702.401900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re ~~MADE~~ Application of:

ROLF BJERKVIG

Int'l Appln. No.: PCT/NO99/00266

Int'l Publn. No.: WO 00/12066

U.S. Appln. No.: 09/763,682

Nat'l Entry Date: February 26, 2001

For: ALGINATE CAPSULES FOR USE  
IN THE TREATMENT OF  
BRAIN TUMOR (As Amended)

: Examiner: Unassigned  
: Group Art Unit: Unassigned

RECEIVED

JUN 01 2001

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Forms PTO-1449. Copies of the listed documents are also enclosed.


Most of the listed documents are noted: (1) in the specification, in which case their relevance can be determined from the discussion in the specification; or in search reports issued in counterpart applications, namely, (2) the Norwegian Search Report or (3) the International Search Report, in which case their relevance can be determined from either search report. A copy of each search report is enclosed. All submitted documents are English.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Forms PTO-1449 be initialled and returned indicating that such information has been considered.

In accordance with 37 C.F.R. § 1.97(b), since the present Information Disclosure Statement is being filed within three months of the entry into the national stage by International Appln. No. PCT/N099/00266, neither a certification, petition, nor payment of a fee is required. Nevertheless, the Commissioner is authorized to charge Deposit Account No. 06-1205 should any fees be associated herewith. A duplicate of this paper is enclosed for this purpose.

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicant  
John W. Behringer  
Registration No. 23,086

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200  
JWB/NMD/ljp:cmv